Lilly guides to $80bn-$83bn 2026 sales as Novo forecasts decline
Lilly expects 25% sales growth at the midpoint and a second-quarter orforglipron launch, while Novo sees sales and profit falling 5% to 13%.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 5 00:25 ETSource: The Cureus Journal of Medical Science
The wire
- 01Lilly forecast 2026 sales of $80 billion to $83 billion against analyst expectations of $77.62 billion; Novo guided to a 5% to 13% drop as US prices fall and exclusivity lapses in China, Brazil and Canada.
- 02Both companies flagged global price declines in the low- to mid-teens percent after the most favored nation deals struck with President Trump in November, with Medicare obesity coverage starting by at least July.
- 03Lilly's oral orforglipron launch is pending US approval and will face Novo's oral Wegovy; CEO David Ricks said 20 million to 25 million patients currently take the two companies' medicines.
From the source
Read at cureus.comPrognostic Value of Blood Ammonia, Lactate, and Brain Natriuretic Peptide in Pediatric Patients With Sepsis: A Prospective, Observational Study
